Treating hyperphosphatemia – current and advancing drugs

References

• Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health. 2008;8:117.
   PubMed Web of Science ®Google Scholar
• Couser WG, Remuzzi G, Mendis S, et al. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011;80:1258–1270.
   PubMed Web of Science ®Google Scholar
• Shanahan CM, Crouthamel MH, Kapustin A, et al. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res. 2011;109(6):697–7114.
   PubMed Web of Science ®Google Scholar
• Shuto E, Taketani Y, Tanaka R, et al. Dietary phosphorus acutely impairs endothelial function. J Am Soc Nephrol. 2009;20:1504–1512.
   PubMed Web of Science ®Google Scholar
• Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. JASN. 2004;15:2208−2218.
   Web of Science ®Google Scholar
• Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant. 2011;26:1948−1955.
   PubMed Web of Science ®Google Scholar
• Cannata-Andía JB, Fernández-Martín JL, Locatelli F, et al. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int. 2013;84:998–1008.
   PubMed Web of Science ®Google Scholar
• Fernández-Martín JL, Martínez-Camblor P, Dionisi MP, et al. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol Dial Transplant. 2015;30:1542–1551.
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Haito-Sugino S, Kuwahara S, et al. Sodium-dependent phosphate cotransporters: lessons from gene knockout and mutation studies. J Pharm Sci. 2011;100:3719−3730.
   PubMed Web of Science ®Google Scholar
• Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol. 2010;21:1427–1435.
   PubMed Web of Science ®Google Scholar
• Moe SM, Duan D, Doehle BP, et al. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int. 2003;63:1003–1011.
   PubMed Web of Science ®Google Scholar
• Shroff RC, McNair R, Skepper JN, et al. Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol. 2010;21:103–112.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes CKDMBDWG. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;76(Suppl 113):S1–S130.
   Google Scholar
• Shinaberger CS, Greenland S, Kopple JD, et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr. 2008;88:1511–1518.
   PubMed Web of Science ®Google Scholar
• Moe SM, Zidehsarai MP, Chambers MA, et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:257–264.
   PubMed Web of Science ®Google Scholar
• Ritz E, Hahn K, Ketteler M, et al. Phosphate additives in food–a health risk. Dtsch Arztebl Int. 2012;109:49–55.
   PubMed Web of Science ®Google Scholar
• Daugirdas JT, Chertow GM, Larive B, et al. Effects of frequent hemodialysis on measures of CKD mineral and bone disorder. JASN. 2012;23:727–738.
   Web of Science ®Google Scholar
• Lopes AA, Tong L, Thumma J, et al. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis. 2012;60:90–101.
   PubMed Web of Science ®Google Scholar
• Isakova T, Gutiérrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. JASN. 2009;20:388–396.
   Web of Science ®Google Scholar
• Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478–1483.
   PubMed Web of Science ®Google Scholar
• Jean G, Lataillade D, Genet L, et al. Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: results from the French ARNOS study. Hemodial Int. 2011;15:485–492.
   PubMed Web of Science ®Google Scholar
• Hill KM, Martin BR, Wastney ME, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3–4 chronic kidney disease. Kidney Int. 2013;83:959–966.
   PubMed Web of Science ®Google Scholar
• Ketteler M, Rix M, Fan S, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol. 2008;3:1125–1130.
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Raggi P. Treat to goal working group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245–252.
   PubMed Web of Science ®Google Scholar
• Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68:1815–1824.
   PubMed Web of Science ®Google Scholar
• Qunibi WY, Hootkins RE, McDowell LL, et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int. 2004;65:1914–1926.
   PubMed Web of Science ®Google Scholar
• Di Iorio B, Bellasi A, Russo D, et al. Mortality in kidney disease patients treated with phosphate binders: a randomized study. CJASN. 2012;7:487–493.
   PubMed Web of Science ®Google Scholar
• Di Iorio B, Molony D, Bell C, et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis. 2013;62:771–778.
   PubMed Web of Science ®Google Scholar
• Patel L, Bernard LM, Elder GJ, et al. Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol. 2016;11:232–244.
   PubMed Web of Science ®Google Scholar
• Brandenburg VM, Schlieper G, Heussen N, et al. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant. 2010;25:2672–2679.
   PubMed Web of Science ®Google Scholar
• Oliveira RB, Cancela AL, Graciolli FG, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol. 2010;5:286–291.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Dimkovic N, Pontoriero G, et al. Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study. Nephrol Dial Transplant. 2010;25:574–581.
   PubMed Web of Science ®Google Scholar
• Sprague SM, Ross EA, Nath SD, et al. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clinical Nephrol. 2009;72:252–258.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A, et al. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant. 2011;26:2567–2571.
   PubMed Web of Science ®Google Scholar
• D’Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl. 2003;85:S73–S78.
   PubMedGoogle Scholar
• Lacour B, Lucas A, Auchère D, et al. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int. 2005;67:1062–1069.
   PubMed Web of Science ®Google Scholar
• Hutchison AJ, Barnett ME, Krause R, et al. Lanthanum Carbonate Study Group. Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis. Clinical Nephrol. 2009;71:286–295.
   PubMed Web of Science ®Google Scholar
• Toussaint ND, Lau KK, Polkinghorne KR, et al. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. Nephrology (Carlton). 2011;16:290–298.
   PubMed Web of Science ®Google Scholar
• De Francisco AL, Leidig M, Covic AC, et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant. 2010;25:3707–3717.
   PubMed Web of Science ®Google Scholar
• Massy ZA, Drueke TB. Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival. Clin Kidney J. 2012;5(Suppl 1):i52–i61.
   Google Scholar
• Cozzolino M, Funk F, Rakov V, et al. Preclinical pharmacokinetics, pharmacodynamics and safety of sucroferric oxyhydroxide. Curr Drug Metab. 2014;15:953–965.
   PubMed Web of Science ®Google Scholar
• Chong E, Kalia V, Willsie S, et al. Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects. J Nephrol. 2014;27:659–666.
   PubMed Web of Science ®Google Scholar
• Wüthrich RP, Chonchol M, Covic A, et al. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol. 2013;8:280–289.
   PubMed Web of Science ®Google Scholar
• Floege J, Covic AC, Ketteler M, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014;86:638–647.
   PubMed Web of Science ®Google Scholar
• Floege J, Covic AC, Ketteler M, et al. Long-term effects of the ironbased phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transpl. 2015;30:1037–1046.
   PubMed Web of Science ®Google Scholar
• Block GA, Fishbane S, Rodriguez M, et al. A 12-week, doubleblind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3–5. Am J Kidney Dis. 2015;65:728–736.
   PubMed Web of Science ®Google Scholar
• Yokoyama K, Hirakata H, Akiba T, et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol. 2014;9:543–552.
   PubMed Web of Science ®Google Scholar
• Lewis JB, Sika M, Koury MJ, et al. Ferric citrate controls phosphorus and delivers iron in citrate’s properties in iron-deficiency and renal anemia in dialysis patients on dialysis. J Am Soc Nephrol. 2015;26:493–503.
   PubMed Web of Science ®Google Scholar
• Umanath K, Jalal DI, Greco BA, et al. Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD. J Am Soc Nephrol. 2015;26:2578–2587.
   PubMed Web of Science ®Google Scholar
• Lee CT, Wu IW, Chiang SS, et al. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study. J Nephrol. 2015;28:105–113.
   PubMed Web of Science ®Google Scholar
• Yokoyama K, Hirakata H, Akiba T, et al. Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial. Am J Nephrol. 2012;36:478–487.
   PubMed Web of Science ®Google Scholar
• Yokoyama K, Akiba T, Fukagawa M, et al. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol Dial Transpl. 2014;29:1053–1060.
   PubMed Web of Science ®Google Scholar
• Virkki LV, Biber J, Murer H, et al. Phosphate transporters: a tale of two solute carrier families. Am J Physiol Renal Physiol. 2007;293:F643–54.
   PubMed Web of Science ®Google Scholar
• Giral H, Caldas Y, Sutherland E, et al. Regulation of rat intestinal Na-dependent phosphate transporters by dietary phosphate. Am J Physiol Renal Physiol. 2009;297:F1466–75.
   PubMed Web of Science ®Google Scholar
• Maccubbin D, Tipping D, Kuznetsova O, et al. Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial. Clin J Am Soc Nephrol. 2010;5:582–589.
   PubMed Web of Science ®Google Scholar
• Spencer AG, Greasley PJ. Pharmacologic inhibition of intestinal sodium uptake: a gut centric approach to sodium management. Curr Opin Nephrol Hypertens. 2015;24:410–416.
   PubMed Web of Science ®Google Scholar
• Nusrat S, Miner PB Jr. New pharmacological treatment options for irritable bowel syndrome with constipation. Expert Opin Emerg Drugs. 2015;20:625–636.
   PubMed Web of Science ®Google Scholar
• Labonté ED, Carreras CW, Leadbetter MR, et al. Gastrointestinal inhibition of sodium-hydrogen exchanger 3 reduces phosphorus absorption and protects against vascular calcification in CKD. J Am Soc Nephrol. 2015;26:1138–1149.
   PubMed Web of Science ®Google Scholar